HK1141249A1 - Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation - Google Patents

Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation

Info

Publication number
HK1141249A1
HK1141249A1 HK10107817.4A HK10107817A HK1141249A1 HK 1141249 A1 HK1141249 A1 HK 1141249A1 HK 10107817 A HK10107817 A HK 10107817A HK 1141249 A1 HK1141249 A1 HK 1141249A1
Authority
HK
Hong Kong
Prior art keywords
treating
receptor agonist
glucocorticoid receptor
compositions
anterior
Prior art date
Application number
HK10107817.4A
Other languages
English (en)
Inventor
Keith Wayne Ward
Claudio Bucolo
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of HK1141249A1 publication Critical patent/HK1141249A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10107817.4A 2007-08-10 2010-08-16 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation HK1141249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95504407P 2007-08-10 2007-08-10
PCT/US2008/072201 WO2009023471A2 (en) 2007-08-10 2008-08-05 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation

Publications (1)

Publication Number Publication Date
HK1141249A1 true HK1141249A1 (en) 2010-11-05

Family

ID=40263555

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107817.4A HK1141249A1 (en) 2007-08-10 2010-08-16 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation

Country Status (19)

Country Link
US (1) US20090042936A1 (el)
EP (1) EP2190431B1 (el)
JP (1) JP5209718B2 (el)
KR (2) KR101298826B1 (el)
CN (1) CN101969950A (el)
AU (1) AU2008287142B2 (el)
BR (1) BRPI0815130A2 (el)
CA (1) CA2694227C (el)
CY (1) CY1114480T1 (el)
DK (1) DK2190431T3 (el)
ES (1) ES2421405T3 (el)
HK (1) HK1141249A1 (el)
HR (1) HRP20130631T1 (el)
MX (1) MX2010001370A (el)
PL (1) PL2190431T3 (el)
PT (1) PT2190431E (el)
SI (1) SI2190431T1 (el)
TW (1) TWI410252B (el)
WO (1) WO2009023471A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US10278810B2 (en) * 2010-04-29 2019-05-07 Ojo, Llc Injectable physiologically adaptive intraocular lenses (IOL's)
US20120316199A1 (en) * 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
MX361886B (es) * 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
US20200330270A1 (en) * 2019-04-18 2020-10-22 Teeny Clean, Llc Device And Method For Stimulating The Meibomian Glands Of The Eyelid
EP3914249B1 (en) 2019-01-22 2024-05-01 Akribes Biomedical GmbH Selective glucocorticoid receptor modifiers for treating impaired skin wound healing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
BR9914158A (pt) * 1998-09-30 2001-06-26 Alcon Lab Inc Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
CA2472746A1 (en) * 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
ES2298508T3 (es) * 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
EP1490317A1 (en) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DK1521733T3 (da) * 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
CA2512257A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP2007530541A (ja) * 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
EP1836166B1 (en) * 2004-12-27 2009-06-17 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PL1944290T3 (pl) * 2005-09-14 2014-07-31 Ayumi Pharmaceutical Corp Nowa pochodna 1-2-dihydrochinoliny mająca aktywność wiązania glukokortykoidowego receptora
SI2049112T1 (sl) * 2006-08-07 2012-05-31 Bausch & Lomb Zdravljenje infekcij in njihovih posledic s kombiniranimi disociiranimi glukokortikoidnimi receptorskimi agonisti in antiinfektivnimi sredstvi
ES2373999T3 (es) * 2006-08-07 2012-02-10 Bausch & Lomb Incorporated Composiciones y métodos para tratar, reducir, mejorar o aliviar enfermedades oftálmicas de segmento posterior.
SI2056799T1 (sl) * 2006-08-31 2013-11-29 Bausch & Lomb Incorporated Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
CA2687948A1 (en) * 2007-05-29 2008-12-04 Mamoru Matsuda Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein andhas glucocorticoid receptor-binding activity
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye

Also Published As

Publication number Publication date
CN101969950A (zh) 2011-02-09
JP5209718B2 (ja) 2013-06-12
MX2010001370A (es) 2010-03-01
AU2008287142B2 (en) 2012-02-02
PL2190431T3 (pl) 2013-11-29
BRPI0815130A2 (pt) 2017-05-09
CY1114480T1 (el) 2016-10-05
DK2190431T3 (da) 2013-09-08
HRP20130631T1 (hr) 2013-08-31
WO2009023471A3 (en) 2009-06-25
ES2421405T3 (es) 2013-09-02
US20090042936A1 (en) 2009-02-12
JP2010535796A (ja) 2010-11-25
KR20100029851A (ko) 2010-03-17
WO2009023471A2 (en) 2009-02-19
KR20120113802A (ko) 2012-10-15
TWI410252B (zh) 2013-10-01
KR101298826B1 (ko) 2013-08-27
AU2008287142A1 (en) 2009-02-19
TW200911286A (en) 2009-03-16
SI2190431T1 (sl) 2013-10-30
EP2190431A2 (en) 2010-06-02
CA2694227A1 (en) 2009-02-19
PT2190431E (pt) 2013-10-09
EP2190431B1 (en) 2013-07-03
CA2694227C (en) 2012-07-03

Similar Documents

Publication Publication Date Title
HK1141249A1 (en) Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
RS52956B (en) CANCER TREATMENT COMPOSITIONS
MX2007016462A (es) Composiciones topicas para tratar la piel.
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
EP2177224A3 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2009025763A3 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CL2008001301A1 (es) Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial.
TW200603838A (en) Extended release biodegradable ocular implants
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
CY1112269T1 (el) Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
WO2008005686A3 (en) Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
MX2010001243A (es) Composicion anti-inflamatoria.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
RU2007138263A (ru) Противовоспалительные соединения
PT2061444E (pt) Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias
PH12014501074A1 (en) Methods of using a thiazole derivative
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170805